Armata Pharmaceuticals, Inc.
ARMP
Rank in Stocks
#18149
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology... Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Share Price
$3.89
Last synced: 2026-11-11
Market Cap
$142.95M
Change (1 day)
3.73%
Change (1 year)
-39.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Armata Pharmaceuticals, Inc. (ARMP)
Category
Healthcare
EPS for Armata Pharmaceuticals, Inc. (ARMP)
EPS as of June 2026 TTM: $-5.30
According to Armata Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-5.30. At the end of 2025 the company had an EPS of $-4.80, a decrease compared to its 2024 EPS of $-0.52.
EPS history for Armata Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.30 | 10.42% |
| 2025 | $-4.80 | 823.08% |
| 2024 | $-0.52 | -72.77% |
| 2023 | $-1.91 | 76.85% |
| 2022 | $-1.08 | 12.50% |
| 2021 | $-0.96 | -28.89% |
| 2020 | $-1.35 | -44.44% |
| 2019 | $-2.43 | -72.70% |
| 2018 | $-8.90 | -68.37% |
| 2017 | $-28.14 | -91.86% |
| 2016 | $-345.80 | 24.12% |
| 2015 | $-278.60 | -147.27% |
| 2014 | $589.40 | -113.16% |
| 2013 | $-4.48K | 2,669.52% |
| 2012 | $-161.76 | -105.98% |
| 2009 | $2.71K | -137.21% |
| 2008 | $-7.27K | 6.26% |
| 2007 | $-6.84K | -71.83% |
| 2006 | $-24.29K | 54.74% |
| 2005 | $-15.70K | 24.97% |
| 2004 | $-12.56K | 873.62% |
| 2003 | $-1.29K | -50.38% |
| 2002 | $-2.60K | -16.13% |
| 2001 | $-3.10K | -50.89% |
| 2000 | $-6.31K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -395.47% |
US
|
|
| $-7.07 | 33.40% |
US
|
|
| $-5.29 | -0.19% |
AU
|
|
| $12.88 | -343.02% |
BE
|
|
| $21.56 | -506.79% |
NL
|
Questions about Armata Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Armata Pharmaceuticals, Inc.'s earnings per share (EPS)?
Armata Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-5.30, as of Jun 2026.
What was Armata Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Armata Pharmaceuticals, Inc.'s earnings per share (EPS) was $-4.80, compared with $-0.52 in 2024.
How has Armata Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Armata Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.52) and lowest in 2025 ($-4.80).
How does Armata Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Armata Pharmaceuticals, Inc.'s earnings per share (EPS) ($-5.30) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.